-
Homepage
-
Formulary Home
-
1 Gastro-intestinal system
-
2 Cardiovascular system
-
3 Respiratory system
-
4 Central nervous system
-
5 Infections
-
6 Endocrine system
-
7 Obstetrics, gynaecology, and urinary-tract disorders
-
8 Malignant disease and immunosuppression
-
8.1 Cytotoxic drugs
-
8.1.1 Alkylating drugs
-
8.1.2 Anthracyclines and other cytotoxic antibiotics
-
8.1.3 Antimetabolites
-
8.1.4 Vinca alkaloids and etoposide
-
8.1.5 Other antineoplastic drugs
-
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) - NICE TAG TA23
-
Breast cancer - trastuzumab - NICE TAG TA34
-
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block- NICE TAG TA55
-
Gastrointestinal stromal tumours - imatinib - NICE TAG TA86
-
Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) - NICE TAG TA91
-
Prostate cancer (hormone-refractory) - docetaxel - NICE TAG TA101
-
Breast cancer (early) - trastuzumab - NICE TAG TA107
-
Breast cancer (early) - paclitaxel - NICE TAG TA108
-
Breast cancer (early) - docetaxel - NICE TAG TA109
-
Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer- NICE TAG TA118
-
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide - NICE TAG TA121
-
Multiple myeloma - bortezomib - NICE TAG TA129
-
Head and neck cancer - cetuximab - NICE TAG TA145
-
Lung cancer (non-small-cell) - erlotinib - NICE TAG TA162
-
Renal cell carcinoma - sunitinib - NICE TAG TA169
-
Head and neck cancer (squamous cell carcinoma) - cetuximab - NICE TAG TA172
-
Colorectal cancer (first line) - cetuximab - NICE TAG TA176
-
Renal cell carcinoma - NICE TAG TA178
-
Gastrointestinal stromal tumours - sunitinib - NICE TAG TA179
-
Cervical cancer (recurrent) - topotecan - NICE TAG TA183
-
Lung cancer (small-cell) - topotecan - NICE TAG TA184
-
Soft tissue sarcoma - trabectedin - NICE TAG TA185
-
Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189
-
Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192
-
Gastrointestinal stromal tumours - imatinib (adjuvant) - NICE TAG TA196
-
Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208
-
Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib - NICE TAG TA209
-
Colorectal cancer (metastatic) - bevacizumab - NICE TAG TA212
-
Breast cancer - bevacizumab (in combination with a taxane) - NICE TAG TA214
-
Pazopanib for the first-line treatment of advanced renal cell carcinoma - NICE TAG TA215
-
Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219
-
Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222
-
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) - NICE TAG TA227
-
Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
-
Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) - NICE TAG TA241
-
Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab - NICE TAG TA242
-
Breast cancer (advanced) - eribulin - NICE TAG TA250
-
Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib - NICE TAG TA251
-
Prostate cancer - cabazitazel - NICE TAG TA255
-
Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) - NICE TAG TA257
-
Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) - NICE TAG TA258
-
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer - NICE TAG TA263
-
Melanoma (stage III or IV) - ipilimumab - NICE TAG TA268
-
Melanoma (BRAF V600 mutation positive, unresectable metastatic) – vemurafenib - NICE TAG TA269
-
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284
-
Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab - NICE TAG TA285
-
Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289
-
Guidance on the use of imatinib for chronic myeloid leukaemia - NICE TAG TA70
-
Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) - NICE TAG TA295
-
Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296
-
Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299
-
Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
-
Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
-
Lung cancer (non small cell, EGFR mutation positive) - afatinib NICE TAG TA310
-
Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311
-
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma - NICE TAG TA319
-
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321
-
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) - NICE TAG TA326
-
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment - NICE TAG TA333
-
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357
-
Ruxolitinib for treating polycythaemia vera (terminated appraisal) - NICE TAG 356
-
Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) - NICE TAG TA353
-
Aflibercept for treating diabetic macular oedema - NICE TAG TA346
-
Everolimus for preventing organ rejection in liver transplantation - NICE TAG TA348
-
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer - NICE TAG TA347
-
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) - NICE TAG TA334
-
Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) - NICE TAG TA328
-
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG 357
-
Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) - NICE TAG TA362
-
Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer - NICE TAG TA360
-
Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359
-
Pembrolizumab for advanced melanoma not previously treated with ipilimumab - NICE TAG TA366
-
Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371
-
Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374
-
Bortezomib for previously untreated mantle cell lymphoma - NICE TAG TA370
-
Nintedanib for treating idiopathic pulmonary fibrosis - NICE TAG TA379
-
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - NICE TAG TA378
-
Panobinostat for treating multiple myeloma after at least 2 previous treatments - NICE TAG TA380
-
Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy - NICE TAG TA381
-
Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis - NICE TAG TA386
-
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer - NICE TAG TA389
-
Nivolumab for treating advanced (unresectable or metastatic) melanoma - NICE TAG TA384
-
Bosutinib for previously treated chronic myeloid leukaemia - NICE TAG TA401
-
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer - NICE TAG TA403
-
Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400
-
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396
-
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel - NICE TAG TA391
-
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395
-
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA406
-
Pegaspargase for treating acute lymphoblastic leukaemia - NICE TAG TA408
-
Talimogene laherparepvec for treating unresectable metastatic melanoma - NICE TAG TA410
-
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer - NICE TAG TA411
-
Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405
-
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA414
-
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer - NICE TAG TA416
-
Nivolumab for previously treated advanced renal cell carcinoma - NICE TAG TA417
-
Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421
-
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422
-
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens - NICE TAG TA423
-
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424
-
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia - NICE TAG TA425
-
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - NICE TAG TA426
-
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy- NICE TAG TA428
-
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
-
Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439
-
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429
-
Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
-
Carfilzomib for previously treated multiple myeloma - NICE TAG TA457
-
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane - NICE TAG TA458
-
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) - NICE TAG TA452
-
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) - NICE TAG TA453
-
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453
-
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA446
-
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA447
-
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease - NICE TAG TA449
-
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451
-
Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA444
-
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
-
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
-
Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA469
-
Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer - NICE TAG TA476
-
Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474
-
Ibrutinib for treating Waldenstrom’s macroglobulinaemia - NICE TAG TA491
-
Vismodegib for treating basal cell carcinoma - NICE TAG TA489
-
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours - NICE TAG TA488
-
Venetoclax for treating chronic lymphocytic leukaemia - NICE TAG TA487
-
Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502
-
Ceritinib for untreated ALK-positive non-small-cell lung cancer - NICE TAG TA500
-
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma - NICE TAG TA498
-
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma - NICE TAG TA505
-
Cabozantinib for treating medullary thyroid cancer - NICE TAG TA516
-
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen - NICE TAG TA515
-
Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA514
-
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma - NICE TAG TA510
-
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer - NICE TAG TA509
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA519
-
Avelumab for treating metastatic Merkel cell carcinoma - NICE TAG TA517
-
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy - NICE TAG TA520
-
Arsenic trioxide for treating acute promyelocytic leukaemia - NICE TAG TA526
-
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA525
-
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA524
-
Midostaurin for untreated acute myeloid leukaemia - NICE TAG TA523
-
Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA522
-
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA531
-
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - NICE TAG TA530
-
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer - NICE TAG TA529
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - NIE TAG TA528
-
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours - NICE TAG TA539
-
Dinutuximab beta for treating neuroblastoma - NICE TAG TA538
-
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer - NICE TAG TA536
-
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
-
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia - NICE TAG TA541
-
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
-
Cabozantinib for untreated advanced renal cell carcinoma - NICE TAG TA542
-
Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma - NICE TAG TA544
-
Gemtuzumab ozogamicin for untreated acute myeloid leukaemia - NICE TAG TA545
-
Vandetanib for treating medullary thyroid cancer - NICE TAG TA550
-
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - NICE TAG TA557
-
Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA555
-
Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence - NICE TAG TA553
-
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years - NICE TAG TA554
-
Lenvatinib for untreated advanced hepatocellular carcinoma - NICE TAG TA551
-
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
-
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) - NICE TAG TA 564
-
Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA563
-
Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA562
-
Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia - NICE TAG TA561
-
Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
-
Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib - NICE TAG TA571
-
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA570
-
Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer - NICE TAG TA569
-
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA567
-
Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TA TAG567
-
Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma - NICE TAG TA577
-
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) - NICE TAG TA576
-
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma - NICE TAG TA573
-
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - NICE TAG TA582
-
Nivolumab with ipilimumab for untreated advanced renal cell carcinoma - NICE TAG TA581
-
Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - NICE TAG TA579
-
Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation - NICE TAG TA578
-
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer - NICE TAG TA584
-
8.2 Drugs affecting the immune response
-
8.3 Sex hormones and hormone antagonists in malignant disease
-
9 Nutrition and blood
-
10 Musculoskeletal and joint diseases
-
10.1 Drugs used in rheumatic diseases and gout
-
10.1.1 Non-steroidal anti-inflammatory drugs
-
10.1.2 Corticosteroids
-
10.1.3 Drugs that suppress the rheumatic disease process
-
Arthritis (juvenile idiopathic) - etanercept - NICE TAG TA35
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab - NICE TAG TA130
-
Ankylosing spondylitis - adalimumab, etanercept and infliximab- NICE TAG TA143
-
Rheumatoid arthritis - certolizumab pegol - NICE TAG TA186
-
Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor - NICE TAG TA195
-
Psoriatic arthritis - etanercept, infliximab and adalimumab - NICE TAG TA199
-
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG445
-
Psoriatic arthritis - golimumab - NICE TAG TA220
-
Rheumatoid arthritis (after failure of previous anti-rheumatic drugs) - golimumab - NICE TAG TA225
-
Ankylosing spondylitis - golimumab - NICE TAG TA233
-
Arthritis (juvenile idiopathic, systemic) - tocilizumab - NICE TAG TA238
-
Rheumatoid arthritis - tocilizumab - NICE TAG TA247
-
Rheumatoid arthritis - abatacept (2nd line) (rapid review of TA234) - NICE TAG TA280
-
Psoriatic arthritis (active) - ustekinumab NICE TAG TA313
-
Apremilast for treating active psoriatic arthritis - NICE TAG TA372
-
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis - NICE TAG TA373
-
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed - NICE TAG TA375
-
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis - NICE TAG TA 383
-
Belimumab for treating active autoantibody-positive systemic lupus erythematosus - NICE TAG TA397
-
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors - NICE TAG TA407
-
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor - NICE TAG TA415
-
Apremilast for treating active psoriatic arthritis - NICE TAG TA433
-
Ustekinumab for moderately to severely active Crohn’s disease after previous treatment - NICE TAG TA456
-
Baricitinib for moderate to severe rheumatoid arthritis - NICE TAG TA466
-
Tofacitinib for moderate to severe rheumatoid arthritis - NICE TAG TA480
-
Sarilumab for moderate to severe rheumatoid arthritis - NICE TAG TA485
-
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA496
-
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA495
-
Golimumab for treating non-radiographic axial spondyloarthritis - NICE TAG TA497
-
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee - NICE TAG TA508
-
Tocilizumab for treating giant cell arteritis - NICE TAG TA518
-
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs - NICE TAG TA543
-
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) - NICE TAG TA568
-
Tildrakizumab for treating moderate to severe plaque psoriasis - NICE TAG TA575
-
Certolizumab pegol for treating moderate to severe plaque psoriasis - NICE TAG TA574
-
10.1.4 Gout and cytotoxic-induced hyperuricaemia
-
10.1.5 Other drugs for rheumatic diseases
-
10.2 Drugs used in neuromuscular disorders
-
10.3 Drugs for the treatment of soft-tissue disorders and topical pain relief
-
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee - NICE TAG TA477
-
11 Eye
-
12 Ear, nose, and oropharynx
-
13 Skin
-
14 Immunological products and vaccines
-
15 Anaesthesia
-
Miscellaneous
-
-
New medicines / ACE
-
Guidelines
-
Shared care
-
Wound care
-
Patient Group Directions (PGDs)
-
FAQs
-
Further information
-
Newsletters
-
Referral forms
-
Self Care
-
Care Homes
-
High Cost Drugs
-
MTRAC
-
COVID-19
© Copyright 2024 NHS. All rights reserved.
